BackLuoxin Pharmaceuticals Group Stock , Ltd. Overview

Luoxin Pharmaceuticals Group Stock , Ltd. EBIT

Latest ebit for 002793.SZ: $-200M, below the sector sector average of $2.4T.

Get informed when a big investor buys or sells

+ Follow

Quarterly EBIT

$34.10M
↑ 262.15% YoY

As of Sep 30, 2026

Annual EBIT (TTM)

-$198.59M
↑ 66.77% YoY

Trailing 12 months ending Sep 30, 2026

Average EBIT (Comparison Companies)

EBIT History

EBIT Comparison

Annual EBIT Growth Rate (%)

Annual EBIT Growth (Absolute)

Luoxin Pharmaceuticals Group Stock , Ltd. (002793.SZ) FAQ

The latest EBIT for 002793.SZ is $-200M as of September 2026. That compares with $-600M in the prior-year period — up 66.8% year over year. That is below the sector sector average of $2.4T. Investors often review this figure alongside Luoxin Pharmaceuticals Group Stock , Ltd.'s historical trend and sector peers before judging valuation or financial health.

Over the past year, 002793.SZ's EBIT moved from $-600M to $-200M — a 66.8% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Luoxin Pharmaceuticals Group Stock , Ltd.'s operating scale or balance-sheet position.

Against its sector companies, 002793.SZ currently prints $-200M for EBIT, while the sector average sits near $2.4T. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Luoxin Pharmaceuticals Group Stock , Ltd.'s growth, margins, and balance sheet.

A EBIT figure of $-200M for 002793.SZ is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $2.4T. Explore the charts below for those layers of context.

After noting 002793.SZ's EBIT ($-200M), review year-over-year change from $-600M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.